CD275 (human)-muIg Fusion Protein (Biotin)
| Code | Size | Price |
|---|
| ANC-575-030-25ug | 25 ug | £572.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Hamster
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Flow Cytometry
Shipping:
BI
Storage:
+4°C
Documents
Further Information
EClass:
32160000
Form (Short):
liquid
Formulation:
50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 5% Glycerol, 0.2% BSA, 0.04% NaN3 (as a preservative).
Handling Advice:
Avoid freeze/thaw cycles.
Labels - Conjugates:
Biotin
Long Description:
Protein. Liquid. 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 5% Glycerol, 0.2% BSA, 0.04% NaN3 (as a preservative). The inducible costimulator CD278 (ICOS) is similar to human CD28 (24% homology), and plays an analogous role in the T cell activation process. Signaling through CD278 is particularly important in progression of TH2 immune response. The receptor for human CD278 (ICOS) is CD275 (GL50), a member of the B7 family sharing ~20% homology with CD80 (B7-1) and CD86 (B7-2). Blockade of the CD278-CD275 interaction in mice improves allograft survival and reduces EAE.
Package Type:
Plastic Vial
Product Description:
The inducible costimulator CD278 (ICOS) is similar to human CD28 (24% homology), and plays an analogous role in the T cell activation process. Signaling through CD278 is particularly important in progression of TH2 immune response. The receptor for human CD278 (ICOS) is CD275 (GL50), a member of the B7 family sharing ~20% homology with CD80 (B7-1) and CD86 (B7-2). Blockade of the CD278-CD275 interaction in mice improves allograft survival and reduces EAE.
Source / Host:
CHO cells
TAGs:
Fc
Transportation:
Non-hazardous
UNSPSC Category:
Other Proteins
UNSPSC Number:
12352202
Use & Stability:
Stable for at least 6 months after receipt when stored at +4°C.
Related Products
| Product Name | Product Code | Supplier | anti-CD275 (human), mAb (ANC4E3) | ANC-263-020 | Ancell | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|